Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.

IF 1.1 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2026-04-01 Epub Date: 2026-03-16 DOI:10.3928/23258160-20260127-02

Nitesh Mohan, Matthew J Schulgit, Victor Bellanda, Gabriel Castilho S Barbosa, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma

{"title":"Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.","authors":"Nitesh Mohan, Matthew J Schulgit, Victor Bellanda, Gabriel Castilho S Barbosa, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma","doi":"10.3928/23258160-20260127-02","DOIUrl":null,"url":null,"abstract":"Background and objective: The aim of this study was to evaluate long-term outcomes of intravitreal faricimab injections (IFIs) in previously treated neovascular age-related macular degeneration (nAMD).Patients and methods: This retrospective cohort included 204 eyes from 178 patients with nAMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Clinical and imaging data were collected at baseline, after three injections, 1 year, 2 years, and final follow-up.Results: Patients were followed for 2.5 ± 0.3 years. Central subfield thickness decreased from 267.6 ± 61.0 µm to 225.8 ± 42.1 µm (P < .001), and treatment intervals extended from 6.5 ± 2.4 to 11.5 ± 8.0 weeks (P < .001). Intraretinal fluid declined from 44.5% to 29.5% (P = .048) and subretinal fluid from 67.5% to 36.8% (P < .001), while vision and pigment epithelial detachment height remained stable. Switching from faricimab to another agent provided no added benefit.Conclusion: Faricimab demonstrated sustained anatomical improvement and treatment durability over 2.5 years, with a subset of patients showing lasting benefit.","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"220-226"},"PeriodicalIF":1.1000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20260127-02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: The aim of this study was to evaluate long-term outcomes of intravitreal faricimab injections (IFIs) in previously treated neovascular age-related macular degeneration (nAMD).

Patients and methods: This retrospective cohort included 204 eyes from 178 patients with nAMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Clinical and imaging data were collected at baseline, after three injections, 1 year, 2 years, and final follow-up.

Results: Patients were followed for 2.5 ± 0.3 years. Central subfield thickness decreased from 267.6 ± 61.0 µm to 225.8 ± 42.1 µm (P < .001), and treatment intervals extended from 6.5 ± 2.4 to 11.5 ± 8.0 weeks (P < .001). Intraretinal fluid declined from 44.5% to 29.5% (P = .048) and subretinal fluid from 67.5% to 36.8% (P < .001), while vision and pigment epithelial detachment height remained stable. Switching from faricimab to another agent provided no added benefit.

Conclusion: Faricimab demonstrated sustained anatomical improvement and treatment durability over 2.5 years, with a subset of patients showing lasting benefit.

查看原文本刊更多论文

法利西单抗治疗新生血管性老年性黄斑变性的长期疗效。

背景和目的：本研究的目的是评估玻璃体内法利西单抗注射（IFIs）治疗先前治疗的新生血管性年龄相关性黄斑变性（nAMD）的长期结果。患者和方法：该回顾性队列包括178例nAMD患者的204只眼睛，这些患者之前接受过抗血管内皮生长因子（anti-VEGF）治疗。在基线、三次注射、1年、2年和最后随访时收集临床和影像学资料。结果：随访时间为2.5±0.3年。中心子野厚度由267.6±61.0µm降至225.8±42.1µm (P < 0.001)，治疗间隔由6.5±2.4周延长至11.5±8.0周（P < 0.001）。视网膜内液从44.5%下降到29.5% (P = 0.048)，视网膜下液从67.5%下降到36.8% (P < 0.001)，而视力和色素上皮脱离高度保持稳定。从faricimab切换到另一种药物没有提供额外的益处。结论：Faricimab显示出持续的解剖改善和治疗持久性超过2.5年，其中一部分患者显示出持久的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.